Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI-Powered blood test could spot five cancers before symptoms show

NCT ID NCT07186296

Diagnosis Sponsor: EXoPERT Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jul 02, 2026 · Updated 3 times

Summary

This study is testing a new blood test called EXoPred that uses artificial intelligence and laser technology to find tiny particles from cancer cells. The goal is to detect breast, colon, pancreatic, ovarian, and lung cancers at an early stage. Researchers will enroll 1,400 people aged 45 and older who have or are suspected of having one of these cancers. The test is not yet proven and this study will help refine the algorithm for future use.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
EXoPred diagnostic test (blood test using AI and laser analysis of particles from cells)
What this could lead to
If successful, this could lead to a simple blood test that catches multiple cancers early, when they are easier to treat.
What could go wrong
This is an early-stage study focused on building and validating the test's algorithm. It may not yet be accurate enough for widespread use, and results need confirmation in larger, more diverse groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 1,400 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2025

Expected to finish

Aug 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Study participants will be collected from hospitals/clinical care settings with access to the intended population.

Ages

45 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Subject aged 45 years or older with a biopsy-proven or clinically suspected primary lung, breast, colorectal, pancreatic, or ovarian cancer, based on objective findings such as radiological, serological, endoscopic, or cytological findings, whose blood was collected prior to any systemic or definitive therapy for the cancer. * Subjects who are willing and able to provide written informed consent. * Subjects who are willing and able to comply with the study requirements. Exclusion Criteria: * Any history of cancer diagnosed and treated within 5 years prior to the date of consent. * Subjects with a history of previous cancer treatment via surgical resection, hormonal cancer treatment, chemotherapy, radiotherapy within the past 6 months for recent cancer diagnosis. * Subjects who have any history of an allogeneic bone marrow, stem cell transplant, or solid organ transplant. * Subjects who are pregnant or breastfeeding women. * Subjects who have consented and have undergone treatment in any other cancer related clinical trials withinthe past 6 months. * Subjects who are currently in active treatment for drug abuse. * Subjects who have received any treatment related to lung, breast, colorectal, pancreatic, or ovarian nodules, such as hormones prior to entering the study. * Unsuitable sample for testing due to contamination, hemolysis, etc.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm colon carcinoma colonic neoplasm colorectal cancer lung cancer lung neoplasm malignant pancreatic neoplasm neoplasm ovarian cancer pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Breast cancer Colon cancer Lung cancer Ovarian cancer Pancreatic cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    9 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Albany Stratton VA Medical Center

    RECRUITING

    Albany, New York, 12208, United States

  • Bronx Veterans Medical Research Foundation

    RECRUITING

    The Bronx, New York, 10468, United States

  • City of Hope Duarte Cancer Center

    RECRUITING

    Los Angeles, California, 91010, United States

  • John Hopkins University

    RECRUITING

    Baltimore, Maryland, 21218, United States

  • KCTL

    RECRUITING

    Louisville, Kentucky, 40202, United States

  • Lexington VA Healthcare System

    RECRUITING

    Lexington, Kentucky, 40502, United States

  • Tibor Rubin VA Medical Center

    RECRUITING

    Long Beach, California, 90822, United States

  • University of Hawaii Cancer Center

    RECRUITING

    Honolulu, Hawaii, 96813, United States

  • VA Hudson Valley Healthcare System

    RECRUITING

    Wappingers Falls, New York, 12590, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.